scholarly journals Arteriovenous Fistula Affects Bone Mineral Density Measurements in End-Stage Renal Failure Patients

2009 ◽  
Vol 4 (9) ◽  
pp. 1494-1499 ◽  
Author(s):  
África Muxí ◽  
José-Vicente Torregrosa ◽  
David Fuster ◽  
Pilar Peris ◽  
Sergi Vidal-Sicart ◽  
...  
1993 ◽  
Vol 13 (2) ◽  
pp. 115-123 ◽  
Author(s):  
Cem Gabay ◽  
Patrick Ruedin ◽  
Daniel Slosman ◽  
Jean-Philippe Bonjour ◽  
Michel Leski ◽  
...  

2016 ◽  
Vol 31 (suppl_1) ◽  
pp. i470-i471 ◽  
Author(s):  
Abay Shepetov ◽  
Gulnar Chingayeva ◽  
Bibigul Abeuova ◽  
Yerkebulan Karibayev ◽  
Makpal Kulkayeva ◽  
...  

1994 ◽  
Vol 45 (1) ◽  
pp. 245-252 ◽  
Author(s):  
Patrick Ruedin ◽  
Rene Rizzoli ◽  
Daniel Slosman ◽  
Michel Leski ◽  
Jean-Philippe Bonjour

2006 ◽  
Vol 30 (S1) ◽  
pp. 337-339 ◽  
Author(s):  
A. Zotti ◽  
M. Caldin ◽  
E. Vettorato ◽  
V. Ferrari ◽  
L. Cavicchioli ◽  
...  

1996 ◽  
Vol 89 (8) ◽  
pp. 457-461 ◽  
Author(s):  
D J Torgerson ◽  
C Donaldson ◽  
D M Reid

Bone mineral density measurements have been criticized on the grounds that they are not a worth-while screening tool. In this paper we argue that bone mineral measurements can be an efficient diagnostic tool even if they are not of proven value for screening. There is complex relationship between the costs of a measurement, the intervention and the predictive value of the test all of which must be accounted for when assessing the value of a bone density measurement. For bone density measurements to be used for screening, a wider evaluation needs to be undertaken compared with that for their use as a diagnostic tool. We address some common objections, for example, that low compliance with screening would undermine efficiency, and show that these are not relevant. Evaluations of screening need to address issues that are likely to affect efficiency.


Bone ◽  
1995 ◽  
Vol 17 (2) ◽  
pp. 157-159 ◽  
Author(s):  
H. Kröger ◽  
P. Vainio ◽  
J. Nieminen ◽  
A. Kotaniemi

2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Moritz Mühlenfeld ◽  
André Strahl ◽  
Ulrich Bechler ◽  
Nico Maximilian Jandl ◽  
Jan Hubert ◽  
...  

Abstract Background Patients with rheumatic diseases have a high risk for joint destruction and secondary osteoarthritis (OA) as well as low bone mineral density (BMD, i.e., osteoporosis). While several factors may lead to low BMD in these patients, the value of BMD measurements in rheumatic patients with end-stage OA scheduled for total joint arthroplasty is unknown. Methods In this retrospective cross-sectional study of 50 adults with secondary OA due to rheumatic diseases, we evaluated dual energy X-ray absorptiometry (DXA) measurements of both hips and the spine performed within 3 months prior to arthroplasty (n = 25 total hip arthroplasty, THA; n = 25 total knee arthroplasty, TKA). We analyzed various demographic and disease-specific characteristics and their effect on DXA results by using group comparisons and multivariate linear regression models. Results Although patients undergoing TKA were younger (63.2 ± 14.2 vs. 71.0 ± 10.8 yr., p = 0.035), osteoporosis was observed more frequently in patients scheduled for TKA than THA (32% vs. 12%). Osteopenia was detected in 13/25 patients (52%) in both the THA and TKA cohort. In the THA cohort, female sex, lower BMI and prednisolone use were associated with lower T-score in the hip. In TKA patients, higher OA grade determined by Kellgren-Lawrence score was associated with lower T-score in the hip of the affected side. Conclusions Osteoporosis is present in a considerable frequency of rheumatic patients with end-stage OA, and THA and TKA patients show distinct frequencies and risk factors of low BMD. Our findings point to a potential value of DXA regarding preoperative evaluation of bone status.


Sign in / Sign up

Export Citation Format

Share Document